Gharib 1 and Castro and Gharib 2 estimated that 300,000 new thyroid gland nodules are detected yearly in the United States, and Solomon 3 estimated that at least 288,000 patients per year undergo thyroid gland fine-needle aspiration (FNA). Assuming a false-negative rate of 5%, a false-positive rate of 3%, a follicular neoplasm diagnostic rate of 11%, 1,4-8 and a nonneoplastic follow-up rate of 20% for patients with a follicular neoplasm, 15,000 patients per year with nonneoplastic disease have surgery and 14,400 patients with neoplastic disease have delays in surgery.
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In practice, the variability in thyroid gland FNA diagnostic accuracy is wide 1,2,4-8 and most likely contributes to regional and institutional differences in patient treatment and outcomes. The literature is replete with studies documenting causes of thyroid gland FNA error, 4, 5, [9] [10] [11] [12] [13] [14] but data are lacking on process improvement studies and determining the successes and failures of attempted error reduction. The national targeting of diagnostic testing from a patient safety viewpoint has lagged behind other quality improvement efforts.
Effective process redesign of diagnostic testing practice entails altering the clinical and pathology domains, and several methods of process redesign are being tested in health care. 15 The Toyota Production System method aptly applies to diagnostic testing because it focuses on product (ie, specimen and diagnosis) quality and the steps involved in testing are similar to the steps involved in manufacturing. 16, 17 Raab et al 18 and Nodit et al 19 reported that the major cause of diagnostic error, including thyroid gland FNA error, was the interpretation of less than optimal samples, leading to false-negative and false-positive diagnoses. Raab et al 20 showed that adoption of Toyota principles in Papanicolaou testing pathway redesign led to improved Papanicolaou test quality and fewer diagnostic errors.
In the present study, we examined thyroid gland FNA error and quality from a Toyota perspective, 16, 21, 22 and we changed specific processes based on error reduction initiatives drawn from the literature and our own root cause analysis. 18 The initiatives consisted of the following: (1) creating an immediate FNA interpretation service [23] [24] [25] and (2) standardizing FNA diagnostic terminology. 4, 26 We hypothesized that the implementation of these initiatives would result in improvement of specimen quality and fewer diagnostic errors. We tested these hypotheses by comparing the thyroid gland FNA specimen adequacy and diagnostic accuracy rates for prestandardized and poststandardized terminology cohorts and immediate and nonimmediate FNA interpretation cohorts.
Materials and Methods

Background
We previously reported institutional performance characteristics of thyroid gland FNA for all patients from January 1, 2003, through December 31, 2004 . 18 Root cause analysis was performed on all cases of false-positive (35 cases) and falsenegative (51 cases) diagnosis. 18 Briefly, our findings showed that the major cause of error was that cytologists made interpretations on less than optimal or noninterpretable specimens. 18 Error reduction initiatives were based on this analysis, a literature review of best practice data, and adoption of Toyota Production System principles. We adopted a Toyota approach to focus on best practices and process rather than individual failings. Internal review board approval was granted before performance of the present study.
Toyota Production System and Error Reduction Interventions
Condel et al 17 compared the diagnostic testing pathway with an industrial production line because the quality of the diagnosis or product depended on the successful completion of a number of sequential steps. In manufacturing, the Toyota Production System simultaneously improves quality, reduces inefficiencies, and lowers costs. Spear and Bowen 21 classified the principles of the Toyota Production System using 4 rules: (1) Pathway rule: The product, information, or service is given its value over simple, predefined, direct pathways without loops or forks. (2) Connection rule: The handoff between 2 people in a pathway is highly specified, direct, and binary with an unambiguous way of making requests and providing responses. (3) Activity rule: The work of an individual is highly specified as to content, sequence, and location. (4) Improvement rule: A problem is immediately fixed toward the ideal state, close to the time, place, and person. A goal in Toyota redesign is moving from the current condition to the ideal state, in which these 4 rules continuously modify practice. 16 
Intervention 1: Development and Use of a Standardized Diagnostic Terminology Scheme
A hypothesized source of error was the failure to use standardized diagnostic criteria in assessing the adequacy of FNA specimens, which led to the making of definitive interpretations on poor quality specimens. 18 The cytologists worked at 2 different hospitals, which led to nonuniform use of terms. For example, some cytologists used descriptive terms for benign specimens (eg, benign follicular cells and colloid), whereas other cytologists used definitively benign diagnoses (eg, benign thyroid nodule). Some cytologists interpreted specimens as nondefinitive if sufficient features for benign or neoplastic lesions were absent; other cytologists preferred to interpret these specimens similarly to benign specimens (ie, with descriptive terms) and used terms less than optimal in describing the adequacy. In the Toyota system, standardizing interpretation is a method of specifying content so that a diagnosis has the same meaning across all cytologists (connection rule). 16, 21, 22 We adopted a version of the Papanicolaou Society terminology scheme. 26 A focus of this study was to evaluate the effectiveness of diagnostic standardization on error proportions and not to study how our standardization scheme compares with other schemes. Three cytologists, representing both hospitals, developed the terminology scheme and created a 15-page document entitled "Application and Interpretation of Thyroid Fine Needle Aspiration Biopsies." This document has been placed on our Agency for Healthcare Research and Quality project Web site and is available on request. Our major focus was standardizing how cytologists classified unsatisfactory, nonspecific, and benign lesions. Criteria for categories, including malignant, follicular neoplasm, and "suspicious" for malignancy were similar to previously published criteria. Minimum criteria for neoplastic entities were not created. The new terminology scheme applied to air-dried and alcohol-fixed slides. The unique aspects of our standardized terminology scheme were as follows: (1) creation of a specimen adequacy scoring system and (2) creation of a nonspecific specimen category.
1. Creation of a specimen adequacy scoring system 27, 28 : An adequacy scoring system was used to evaluate overall specimen quality to assist the cytologists in not making definitive diagnoses on noninterpretable specimens. The scoring system was based on the grading of 3 criteria:
(1) follicular cell cellularity; (2) amount of colloid; and (3) degree of preservation, presence of obscuring factors, and preparation limitations. Each criterion was graded on a 0 to 3 scale, and the overall score was based on summing the individual criterion grade. Specimens with a summed adequacy score of 5 or less were classified as nonspecific. 2. Creation of a nonspecific specimen category: Benign lesions were subclassified into categories (eg, benign colloid nodule and benign colloid nodule with involution) with well-defined criteria. Patient specimens that did not show these specific benign criteria and also lacked neoplastic features were diagnosed as nonspecific. Nonspecific specimens were considered less than optimal and not definitive of any entity. These specimens were not considered benign or neoplastic and were considered a type of noninterpretable specimen, closely related to unsatisfactory specimens. Compared with unsatisfactory specimens, nonspecific specimens showed minimum criteria for adequacy. However, nonspecific specimens could not be classified definitively as benign because a sufficient amount of colloid or sufficient number of benign follicular cells was absent. No atypical cells were present in a nonspecific specimen. The 3 cytologists drafted the standardized terminology document that was shared with the other cytologists and members of the cytology unit. The cytologists who drafted the document were viewed as the opinion leaders, and feedback was provided to them. A number of drafts were produced based on discussion. The standardized terminology intervention was implemented on January 1, 2005. The opinion-leader cytologists served as experts and fielded questions on terminology classification. If one cytologist thought a specimen was nonspecific, a second cytologist was consulted on the case. Discordance was handled by discussion or showing the specimen to a third cytologist. A total of 8 cytologists and 6 cytotechnologists began using the new terminology scheme.
Intervention 2: Expansion of an Immediate Interpretation Service
Immediate interpretation improves specimen quality by simultaneously targeting the procurement and interpretation processes and providing immediate information for the aspirator. Although an immediate interpretation service was in existence before 2005, the hospital administration and pathology department initiated an effort to increase the number of cytologist-performed FNAs and to increase the number of immediate interpretations for radiologically performed FNAs. Cytologists performed the immediate interpretation. To increase the number of cytologist-performed FNAs, cytologists with expertise in performing FNAs were recruited, pathologic-clinical seminars were conducted, FNA brochures were mailed to clinicians, and the hospital administration encouraged clinicians to send patients with palpable lesions to a cytologist-run FNA clinic. Meetings were held with radiologists to increase the number of immediate interpretations in radiology. In the Toyota system, the immediate interpretation service was an example of a simple, predefined pathway (pathway rule) that connected the patient, pathologist, and radiologist (connection rule). 16, 21, 22 The FNA could be repeated until the cytologist knew that the specimen was unambiguous and of sufficient quality for interpretation, thereby ensuring adequacy of the sample.
Study Cohort Identification
We examined the effect of the 2 interventions on the outcome measures of individual cohorts that were identified by a search of the laboratory information system (CoPathPlus Anatomic Pathology, Cerner, Kansas City, MO).
For the analysis of the effect of diagnostic terminology standardization, the prestandardization cohort included all patients who had a thyroid gland FNA between January 
Outcome Measures
Outcomes measures included accuracy and nonaccuracy performance metrics. The accuracy performance metrics were sensitivity and specificity and the number and frequency of cytologic-histologic correlation discrepant case pairs, falsenegative diagnoses, and false-positive diagnoses. Overall diagnostic accuracy was measured by using receiver operating characteristic (ROC) curves. 18 Performance measures of accuracy were based on histologic follow-up, which was considered the "gold standard." The nonaccuracy performance metrics were the number and frequency of noninterpretable specimens, patients undergoing surgery, repeated FNA, and atypical diagnoses. We assumed that lower nonaccuracy performance metric values represented higher quality.
Diagnostic Classification and Histologic Follow-up
For analysis, FNA diagnoses were classified into the following categories: unsatisfactory, nonspecific, benign, atypical, follicular or Hürthle cell lesion or neoplasm, suspicious for malignancy, or malignant. 29 We searched the laboratory information system from the day of the FNA to February 5, 2006 , to retrieve histologic follow-up for each patient. For the pre-and post-terminology standardization cohorts, histologic follow-up was obtained for 364 (23.6%) and 234 (19.9%) cases, respectively. For the nonimmediate and immediate interpretation cohorts, histologic follow-up was obtained for 183 (20.8%) and 51 (17.3%) cases, respectively. The follow-up timeframe ranged from the same day to 14 months after the FNA specimen was obtained; the mean follow-up time was 2.0 months. The final histologic diagnosis was coded as benign, atypical, follicular or Hürthle cell adenoma, or malignant. Cases with a histologic diagnosis of microscopic papillary carcinoma were coded as benign diagnoses for analysis because these diagnoses were incidental to the process.
Data Analysis
All cases without histologic follow-up were excluded from diagnostic accuracy calculations. For the calculation of sensitivity, we included FNA diagnoses of follicular or Hürthle cell lesion or neoplasm, suspicious, and malignant and histologic follow-up diagnoses of follicular or Hürthle cell neoplasm or malignant as a true-positive; we included an FNA diagnosis of benign and a histologic follow-up diagnosis of follicular or Hürthle cell neoplasm or malignant as a false-negative. 18, 29 We recognize that the inclusion criteria of FNA cases only with histologic follow-up represented a verification bias. For the calculation of specificity, we included only an FNA diagnosis of benign and a histologic follow-up diagnosis of benign as a truenegative; we included FNA diagnoses of follicular or Hürthle cell lesion or neoplasm, suspicious, and malignant and a histologic follow-up diagnosis of benign as a false-positive. We excluded cases with FNA or histologic diagnoses of atypical, nonspecific, and unsatisfactory from these calculations.
We calculated the number of discrepant cytologic-histologic correlation case pairs by measuring 2-step or greater differences between the FNA and histologic diagnoses. 29 We excluded the FNA diagnoses of unsatisfactory, nonspecific, and atypical. 30 The false-negative diagnostic rate was defined as the number of false-negative diagnoses divided by the number of true-negative plus false-negative diagnoses. The falsepositive diagnostic rate was defined as the number of falsepositive diagnoses divided by the number of true-positive plus false-positive diagnoses.
The noninterpretable specimen rate was defined as the number of unsatisfactory and nonspecific specimens divided by the total number of specimens. The atypical diagnostic rate was defined as the number of atypical diagnoses divided by the total number of diagnoses. The surgery rate was defined as the number of patients with an FNA and surgical excision divided by the number of patients with an FNA. The repeated FNA rate was defined as the number of FNAs with follow-up of a repeated FNA divided by the number of FNAs.
Differences in proportions of the accuracy and nonaccuracy performance metrics for each of the 2 cohorts were examined by using the χ 2 test. Statistical significance was assumed with a P value of .05 or less. Likelihood ratios were calculated for the individual diagnostic categories. 30, 31 We calculated overall diagnostic accuracy by measuring the area under the ROC curve. 30, 31 Diagnoses of unsatisfactory and nonspecific specimens were excluded in the ROC curve analysis. The SE was calculated with a nonparametric assumption.
Results
❚Table 1❚ shows the number of FNA diagnoses by diagnostic category in the pre-and post-terminology standardization cohorts and in the immediate and nonimmediate interpretation cohorts. For the terminology standardization cohorts, there was a statistically significant difference in diagnostic category use (P < .001) with more nonspecific diagnoses and fewer atypical diagnoses in the post-terminology standardization cohort. ❚Table 2❚ shows the FNA and histologic follow-up diagnoses for the pre-and post-terminology standardization cohorts. ❚Table 3❚ shows the FNA and histologic follow-up diagnoses for the nonimmediate and immediate interpretation cohorts. The likelihood ratios for the diagnostic categories are shown.
❚Table 4❚ shows the FNA performance metrics for the terminology standardization and immediate interpretation cohorts. The post-terminology standardization cohort had a higher noninterpretable specimen rate because 155 (13.2%) of the specimens were classified as nonspecific, a category that had not been used previously. For the post-terminology standardization cohort, significantly fewer patients had surgery, a false-negative diagnosis, repeated FNA, or an atypical diagnosis. The sensitivity increased significantly because fewer false-negative diagnoses were made. For the post-terminology standardization cohort, the false-positive rate increased slightly and the specificity decreased, although these changes were not statistically significant.
Compared with cases without immediate interpretation, cases with immediate interpretation had significantly lower noninterpretable specimen and repeated FNA rates. The majority of the other performance metrics improved slightly for cases with immediate interpretation, but this improvement was not statistically significant. The greatest improvement in FNA performance was observed in cases with immediate interpretation using the standardized terminology; these cases had high interpretable specimen rate and sensitivity. ❚Table 5❚ shows the area under the curve for the terminology standardization and immediate interpretation cohorts. Compared with the pre-terminology standardization cohort, the post-terminology standardization cohort had statistically significant higher diagnostic accuracy (P = .05). There was no statistically significant difference in accuracy for the immediate and nonimmediate interpretation cohorts (P = .858).
Discussion
Our findings indicate that the process of systematic error data collection, root cause analysis, and design and implementation of error reduction plans based on Toyota principles may improve the performance of cytologic diagnostic testing for patients who have a thyroid gland nodule. The process of standardizing FNA diagnostic terminology alone improved diagnostic accuracy but led to a significant increase in the noninterpretable specimen rate. The addition of immediate interpretation resulted in a significant decrease in the noninterpretable specimen rate while maintaining high diagnostic accuracy.
Our error reduction initiatives focused on reducing the number of definitive interpretations being made on poor quality specimens. 18, 32 Toyota principles focus on producing only high-quality products, and, therefore, are at odds with the practice of making diagnoses on "satisfactory" but very poor quality specimens. 16 Existing thyroid gland FNA adequacy criteria schemes vary in their stringency and, consequently, trade off false-negative and false-positive rates with unsatisfactory specimen rates. 4, 26 As a consequence, the problem of poor specimen quality is not addressed. The creation of the diagnostic category of nonspecific raised the bar on specimen quality, increased FNA sensitivity, and lowered the atypical rate. However, the nonspecific category was problematic for clinicians who had to make management decisions for patients with nondefinitive diagnoses. [5] [6] [7] The solution to lower the nondefinitive diagnostic rate was the immediate interpretation service that targeted the quality problem at the sharp edge of care when the specimen is procured. Immediate interpretation has been shown to improve specimen adequacy and diagnostic accuracy in cytology and even surgical pathology through the use of intraoperative frozen section assessment. 16, 21, 22 In our study, the immediate interpretation service lowered the noninterpretable rate from 23.8% to 7.8% and the repeated FNA rate from 9.5% to 3.7%. Immediate interpretation also illustrates the Toyota principle of producing an excellent quality product by enhancing communication. 16 Arguments against immediate interpretation focus mainly on increased costs 33 but do not adequately measure benefits, including improved patient safety. Neither intervention significantly lowered the false-positive rate, indicating that factors other than specimen quality most likely contributed to these errors. The majority of falsepositives were derived from the follicular/Hürthle cell neoplasm category, and the literature indicates that up to 20% of specimens with this diagnosis have nonneoplastic histologic follow-up. 1, 4 A traditional view is that this error frequency is irreducible, 4 although the published frequency varies widely, indicating that error reduction may be possible with standardization. Root cause analysis has shown that some false-positive diagnoses are secondary to patient-related factors because some nonneoplastic lesions are cytologically inseparable from adenomas. 18 Expert cytologists have published criteria to separate adenomas from nonneoplastic entities, and we attempted to use these criteria in our system. 4 Our previous study indicated that individual cytologists had varied accuracy using this category, and learning from these cytologists is a source of future study and potential improvement. 18 Our error reduction initiatives were neither novel nor complex, and some have argued that immediate interpretation should be the standard of care. Our challenges were the recognition that a problem existed and improvement was possible. Introducing change is difficult because of underlying biases and the belief that the current system is satisfactory or even highly competent. A small group of cytologists were motivated to change because they had been participating in an Agency for Healthcare Research and Quality-funded study that benchmarked errors detected by the cytologic-histologic correlation process. 29 Although many laboratories track errors detected by this process, there is a general lack of expertise on devising error reduction initiatives based on correlation data. 34 A problem has been that laboratories traditionally do not view error as a result of process failure, but rather adjudicate error as a clinician error in procurement or a cytologist misinterpretation. 29, 35 A reason that we adopted a Toyota approach was that we did not want to focus on individual failings, but rather wanted to target process redesign.
The introduction of the new terminology scheme resulted in a management dilemma because more patients had noninterpretable specimens. We attempted to create departmental solidarity in this effort by having 2 cytologists review every specimen with a diagnosis of nonspecific. The clinicians were asked for input before the introduction of the new terminology scheme. Recently, some pathologists in our department recommended that patients with a benign thyroid FNA diagnosis have a follow-up FNA because a single benign diagnosis had a high probability of being a false-negative. 36 The new terminology scheme was an effort to reduce the number of repeated FNAs and false-negative diagnoses, and this information was conveyed to the clinical staff.
A limitation in this study was that we simultaneously introduced 2 practice changes, and the separate effects of terminology standardization and immediate interpretation were not directly measurable. Improvement may have been related to the Hawthorne effect, with cytologists and clinicians improving performance because of increased focus. 37, 38 Changes in performance also may have been related to other alterations in practice that we were unable to track. The ability for other institutions to adopt these improvements is unknown, and Toyota principles indicate that the understanding of local environments is critical for success.
We conclude that the lack of standardized diagnostic terminology and the lack of immediate interpretation services contribute to the wide variability in the reported diagnostic accuracy of thyroid gland FNA. Simultaneously targeting specimen procurement and interpretation by focusing on process, rather than on individuals, is a means to improve accuracy.
